Zhong Lun and Haiwen advise on Listing of Lepu Biopharma on HKEX
2022-02-25

Lepu Biophamar Co.ltd ("Lepu Biopharma") made its IPO of H shares and listed on the Main Board of the Hong Kong Stock Exchange on 23 February 2022 (stock code: 2157). The global offering of a total of 126,876,000 shares at an offer price of HK$7.13 per share, with net proceeds of over HK$800 million (before the exercise of the over-allotment option).

Lepu Biopharma is an innovative biopharmaceutical company focusing on the field of oncology therapy based in China and facing the world.

For this IPO, Zhong Lun and Clifford Chance were its corporate PRC counsel and corporate Hong Kong counsel respectively; Haiwen and Herbert Smith Freehills were its brokerage firm PRC counsel and brokerage firm Hong Kong counsel respectively.